Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer

You may be eligible if

• Inclusion:
• 1. DISEASE CHARACTERISTICS: Histologically proven or suspicious primary or metastatic colorectal carcinoma undergoing disease resection
• 2. PATIENT CHARACTERISTICS:A. Age: 19 and over
• 3. Performance status: Karnofsky 60-100%
• 4. Not pregnant or nursing Fertile patients must use effective contraception during and for at least 1 month after study
• 5. PRIOR CONCURRENT THERAPY:
• 6. Subject has had at least 8 weeks since prior fluorouracil, capecitabine, fluorouracil-uracil, floxuridine, or S-1 Endocrine therapy:
• 7. No prior or concurrent steroids Radiotherapy:
• 8. Surgery: No prior emergent surgery (e.g., perforation or obstruction) No prior transplantation
• 9. At least 8 weeks since any prior drug metabolized by dihydropyrimidine dehydrogenase enzyme At least 8 weeks since prior flucytosine
• Exclusion:
• 1. Severe infection(White Blood Cell Count)WBC\>2 times normal
• 2. Fever
• 3. Sepsis
• 4. Subject on immunosuppressives therapy
• 5. Subjects will serum Bilirubin/Creatinine\>2 times normal levels
• 6. Pregnant /Lactating women
• 7. Subjects that have received eniluracil or 5-FU(Fluorouracil) within 28 days prior to randomization
• 8. Subject that have comorbidity illnesses that will increase the likelihood of there death in \<5 years